203Pb

1 stories · following the connections

Business

RadioMedix Inc. and AREVA Med Announce Completion of the Exploratory Clinical Trial of 203Pb-AR-RMX in patients expressing somatostatin receptor positive neuroendocrine tumors

By Nasdaq OMXJun 22, 2017, 8:00 PM UTC